Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11067588 | 0.97 | LMNA (0.62) | LMNABLMPTPN1MEN1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL3077265 | 0.97 | LMNA (0.62) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL28570902 | 0.91 | LMNA (0.54) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL11501559 | 0.89 | LMNA (0.52) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL28587849 | 0.88 | LMNA (0.56) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL4761652 | 0.88 | LMNA (0.56) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL4761593 | 0.85 | LMNA (0.48) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL14413849 | 0.85 | LMNA (0.48) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL538230 | 0.83 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL8672325 | 0.83 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795466-B2 | Method for producing saturated nitriles | BASF AKTIENGESELLSCHAFT (DE) | 2010-09-14 | — | — | US | disclosed |
| EP-1868988-B1 | METHOD FOR PRODUCING SATURATED NITRILES | BASF SE (DE) | 2008-10-08 | — | — | EP | disclosed |
| US-20080177100-A1 | Method For Producing Saturated Nitriles | BASF AKTIENGEELLSCHAFT (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1868988-A1 | METHOD FOR PRODUCING SATURATED NITRILES | BASF AKTIENGESELLSCHAFT (DE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106141-A1 | METHOD FOR PRODUCING SATURATED NITRILES | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177100-A1 | Method For Producing Saturated Nitriles | GGPS1, NOS2, NOS1 | LMNA 2597/4885BLM 4452/4885PTPN1 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.